Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Conditional survival for longer-term survivors from 2000–2004 using population-based cancer registry data in Osaka, Japan

Authors: Yuri Ito, Tomio Nakayama, Isao Miyashiro, Akiko Ioka, Hideaki Tsukuma

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

We usually report five-year survival from population-based cancer registries in Japan; however these survival estimates may be pessimistic for cancer survivors, because many patients with unfavourable prognosis die shortly after diagnosis. Conditional survival can provide relevant information for cancer survivors, their family and oncologists.

Methods

We used the period approach to estimate the latest 10-year survival of 38,439 patients with stomach, colorectal, lung, breast and prostate cancer diagnosed between 1990 and 2004 and followed-up from 2000–04 in Osaka, Japan. Conditional survival is an estimate, with the pre-condition of having already survived a certain length of time. Conditional five-year relative survival of one to five years after diagnosis was calculated by site, age and stage for survivors under the age of 70.

Results

Five-year relative survival for stomach cancer was 60%. Conditional five-year relative survival was 77% one year after diagnosis and 97% five years after diagnosis. This means that 97% of patients who survive five years after diagnosis can survive a further five years. Conditional five-year relative survival improved successively with each additional year that patients lived after diagnosis for stomach, colorectal and lung cancer. These figures for breast and prostate cancer were stable at high survival. Liver cancer did not show an increase in conditional five-year survival.

Conclusion

Conditional five-year survival is a relevant figure for long-term cancer survivors in Japan. It is important for population-based cancer registries to provide figures which cancer patients and oncologists really need.
Appendix
Available only for authorised users
Literature
1.
go back to reference National Research Council: 2 Cancer Survivors. From Cancer Patient to Cancer Survivor: Lost in Transition. Edited by: Hewitt M, Greenfield S, Stovall E. 2005, Washington D.C.: The National Academies Press, 23-65. National Research Council: 2 Cancer Survivors. From Cancer Patient to Cancer Survivor: Lost in Transition. Edited by: Hewitt M, Greenfield S, Stovall E. 2005, Washington D.C.: The National Academies Press, 23-65.
2.
go back to reference Yu XQ, Baade PD, O’Connell DL: Conditional survival of cancer patients: an Australian perspective. BMC Cancer. 2012, 12: 460-10.1186/1471-2407-12-460.CrossRefPubMedPubMedCentral Yu XQ, Baade PD, O’Connell DL: Conditional survival of cancer patients: an Australian perspective. BMC Cancer. 2012, 12: 460-10.1186/1471-2407-12-460.CrossRefPubMedPubMedCentral
3.
go back to reference Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, Ameijide A, Siesling S, Mangone L, Ardanaz E, et al: Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. Int J Cancer. 2013, 132 (10): 2404-2412. 10.1002/ijc.27895.CrossRefPubMed Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, Ameijide A, Siesling S, Mangone L, Ardanaz E, et al: Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. Int J Cancer. 2013, 132 (10): 2404-2412. 10.1002/ijc.27895.CrossRefPubMed
4.
go back to reference Abbott AM, Habermann EB, Parsons HM, Tuttle T, Al-Refaie W: Prognosis for primary retroperitoneal sarcoma survivors: a conditional survival analysis. Cancer. 2012, 118 (13): 3321-3329. 10.1002/cncr.26665.CrossRefPubMed Abbott AM, Habermann EB, Parsons HM, Tuttle T, Al-Refaie W: Prognosis for primary retroperitoneal sarcoma survivors: a conditional survival analysis. Cancer. 2012, 118 (13): 3321-3329. 10.1002/cncr.26665.CrossRefPubMed
5.
go back to reference Ellison LF, Bryant H, Lockwood G, Shack L: Conditional survival analyses across cancer sites. Health Rep. 2011, 22 (2): 21-25.PubMed Ellison LF, Bryant H, Lockwood G, Shack L: Conditional survival analyses across cancer sites. Health Rep. 2011, 22 (2): 21-25.PubMed
6.
go back to reference Baade PD, Youlden DR, Chambers SK: When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust. 2011, 194 (2): 73-77.PubMed Baade PD, Youlden DR, Chambers SK: When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust. 2011, 194 (2): 73-77.PubMed
7.
go back to reference Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN: Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010, 116 (9): 2234-2241.PubMedPubMedCentral Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN: Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010, 116 (9): 2234-2241.PubMedPubMedCentral
8.
go back to reference Merrill RM, Hunter BD: Conditional survival among cancer patients in the United States. Oncologist. 2010, 15 (8): 873-882. 10.1634/theoncologist.2009-0211.CrossRefPubMedPubMedCentral Merrill RM, Hunter BD: Conditional survival among cancer patients in the United States. Oncologist. 2010, 15 (8): 873-882. 10.1634/theoncologist.2009-0211.CrossRefPubMedPubMedCentral
9.
go back to reference Janssen-Heijnen ML, Houterman S, Lemmens VE, Brenner H, Steyerberg EW, Coebergh JW: Prognosis for long-term survivors of cancer. Ann Oncol. 2007, 18 (8): 1408-1413. 10.1093/annonc/mdm127.CrossRefPubMed Janssen-Heijnen ML, Houterman S, Lemmens VE, Brenner H, Steyerberg EW, Coebergh JW: Prognosis for long-term survivors of cancer. Ann Oncol. 2007, 18 (8): 1408-1413. 10.1093/annonc/mdm127.CrossRefPubMed
10.
go back to reference Skuladottir H, Olsen JH: Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003, 21 (16): 3035-3040. 10.1200/JCO.2003.04.521.CrossRefPubMed Skuladottir H, Olsen JH: Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003, 21 (16): 3035-3040. 10.1200/JCO.2003.04.521.CrossRefPubMed
11.
go back to reference Bryant H, Lockwood G, Rahal R, Ellison L: Conditional survival in Canada: adjusting patient prognosis over time. Current oncol (Toronto Ont). 2012, 19 (4): 222-224. Bryant H, Lockwood G, Rahal R, Ellison L: Conditional survival in Canada: adjusting patient prognosis over time. Current oncol (Toronto Ont). 2012, 19 (4): 222-224.
13.
go back to reference World Health Organization: International Classification of Diseases, 10th revision. World Health Organization: International Classification of Diseases, 10th revision.
14.
go back to reference Berkson J, Gage R: Calculation of survival rates for cancer. Proceed Staff Meeting Mayo Clinic. 1950, 25: 270-286. Berkson J, Gage R: Calculation of survival rates for cancer. Proceed Staff Meeting Mayo Clinic. 1950, 25: 270-286.
15.
go back to reference Esteve J, Benhamou E, Croasdale M, Raymond L: Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990, 9 (5): 529-538. 10.1002/sim.4780090506.CrossRefPubMed Esteve J, Benhamou E, Croasdale M, Raymond L: Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990, 9 (5): 529-538. 10.1002/sim.4780090506.CrossRefPubMed
16.
go back to reference Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine: strel computer program version 1.2.7 for cancer survival analysis. 2009 Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine: strel computer program version 1.2.7 for cancer survival analysis. 2009
18.
go back to reference Brenner H, Gefeller O: Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol. 1997, 50 (2): 211-216. 10.1016/S0895-4356(97)00280-1.CrossRefPubMed Brenner H, Gefeller O: Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol. 1997, 50 (2): 211-216. 10.1016/S0895-4356(97)00280-1.CrossRefPubMed
19.
go back to reference Rubin DB: Multiple Imputation for Nonresponse in Surveys. 1987, New York: John Wiley & SonsCrossRef Rubin DB: Multiple Imputation for Nonresponse in Surveys. 1987, New York: John Wiley & SonsCrossRef
20.
go back to reference StataCorp: Stata Statistical Software: Release 12. College Station. 2011, TX: StataCorp LP StataCorp: Stata Statistical Software: Release 12. College Station. 2011, TX: StataCorp LP
21.
go back to reference Verdecchia A, De Angelis R, Capocaccia R, Sant M, Micheli A, Gatta G, Berrino F: The cure for colon cancer: results from the EUROCARE study. Int J Cancer. 1998, 77 (3): 322-329. 10.1002/(SICI)1097-0215(19980729)77:3<322::AID-IJC2>3.0.CO;2-Q.CrossRefPubMed Verdecchia A, De Angelis R, Capocaccia R, Sant M, Micheli A, Gatta G, Berrino F: The cure for colon cancer: results from the EUROCARE study. Int J Cancer. 1998, 77 (3): 322-329. 10.1002/(SICI)1097-0215(19980729)77:3<322::AID-IJC2>3.0.CO;2-Q.CrossRefPubMed
22.
go back to reference Lambert PC, Thompson JR, Weston CL, Dickman PW: Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007, 8 (3): 576-594.CrossRefPubMed Lambert PC, Thompson JR, Weston CL, Dickman PW: Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007, 8 (3): 576-594.CrossRefPubMed
23.
go back to reference Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, Katai H, Tsujitani S, Kodera Y, Seto Y, et al: Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric cancer official j Int Gastric Cancer Association Japanese Gastric Cancer Association. 2011, 14 (4): 301-316. Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, Katai H, Tsujitani S, Kodera Y, Seto Y, et al: Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric cancer official j Int Gastric Cancer Association Japanese Gastric Cancer Association. 2011, 14 (4): 301-316.
24.
go back to reference Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, Sobue T: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008, 38 (4): 259-267. 10.1093/jjco/hyn017.CrossRefPubMed Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, Sobue T: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008, 38 (4): 259-267. 10.1093/jjco/hyn017.CrossRefPubMed
25.
go back to reference Toyoda Y, Nakayama T, Ioka A, Tsukuma H: Trends in lung cancer incidence by histological type in Osaka. Japan Jpn J Clin Oncol. 2008, 38 (8): 534-539. 10.1093/jjco/hyn072.CrossRefPubMed Toyoda Y, Nakayama T, Ioka A, Tsukuma H: Trends in lung cancer incidence by histological type in Osaka. Japan Jpn J Clin Oncol. 2008, 38 (8): 534-539. 10.1093/jjco/hyn072.CrossRefPubMed
26.
go back to reference Devesa SS, Bray F, Vizcaino AP, Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005, 117 (2): 294-299. 10.1002/ijc.21183.CrossRefPubMed Devesa SS, Bray F, Vizcaino AP, Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005, 117 (2): 294-299. 10.1002/ijc.21183.CrossRefPubMed
27.
go back to reference de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012, 13 (6): 607-615. 10.1016/S1470-2045(12)70137-7.CrossRefPubMed de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012, 13 (6): 607-615. 10.1016/S1470-2045(12)70137-7.CrossRefPubMed
Metadata
Title
Conditional survival for longer-term survivors from 2000–2004 using population-based cancer registry data in Osaka, Japan
Authors
Yuri Ito
Tomio Nakayama
Isao Miyashiro
Akiko Ioka
Hideaki Tsukuma
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-304

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine